Kaitlyn D’Onofrio

DocwireNews

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about the extended approval of ixekizumab, a comparison of reference adalimumab versus a biosimilar, sarilumab’s safety and efficacy, and the effect of the COVID-19 pandemic on spine surgeons.
Eli Lilly and Company received an additional approved <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/eli-lilly-drug-ixekizumab-receives-expanded-approval-for-non-radiographic-axial-spondyloarthritis/">indication for its drug Taltz® (ixekizumab)</a>, which is now approved to treat active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation. The approval is a milestone for Lilly, as ixekizumab is the first IL-17A antagonist to receive the FDA’s approval for nr-axSpA. Ixekizumab was first approved by the FDA in 2016 to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (this was expanded in March of this year to include pediatric patients). In 2017, the drug was also approved to treat adults with active psoriatic arthritis. Then, in 2019, it was approved to treat adults with active axSpA.
Researchers recently compared the safety, efficacy, and pharmacodynamics of <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/eli-lilly-drug-ixekizumab-receives-expanded-approval-for-non-radiographic-axial-spondyloarthritis/">adalimumab manufactured by Hetero</a> and marketed as Mabura, versus reference adalimumab manufactured by Abbvie and marketed as Humira. “Results of this study demonstrated no clinically meaningful difference in efficacy, pharmacodynamics, and safety between test and reference treatment groups. Hence, the test adalimumab is being equally efficacious and safe biosimilar to the reference adalimumab for treatment of active [rheumatoid arthritis] RA in patients concomitantly on [methotrexate] therapy,” they concluded.
Researchers recently assessed the <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/sarilumab-alone-or-in-combination-with-conventional-synthetic-dmards-safe-and-effective-for-most-ra-patients/">safety and efficacy of sarilumab</a> either as a monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with varying severities of RA. Overall, sarilumab was clinically superior as a monotherapy compared to adalimumab as well as in combination with csDMARDs compared to placebo plus csDMARDs across all patient demographic, disease characteristics, and prior treatments subgroups.
<a href="https://www.docwirenews.com/condition-center/orthopedicscc/orthopedics-center-picks/how-has-the-covid-19-pandemic-impacted-spine-surgeons/">Orthopedic surgeons were significantly impacted by the COVID-19 pandemic</a>, and a recent analysis forecasted that surgery volume will not return to prepandemic levels for at least a year. An estimated 83.5% of all orthopaedic surgeries were delayed due to the <a href="https://www.docwirenews.com/home-page-editor-picks/the-covid-19-pandemic-latin-america-the-new-epicenter-company-starts-first-human-trial-of-coronavirus-antibody-therapy/">pandemic</a>. Of the estimated 16.5% that were permitted to go as scheduled, these were traumas, amputations, and oncological procedures; dislocations and fractures were performed if they were considered urgent cases. However, there are less data on how the pandemic has affected subspecialties.

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about the extended approval of ixekizumab, a comparison of reference adalimumab versus a biosimilar, sarilumab’s safety and efficacy, and the effect of the COVID-19 pandemic on spine surgeons.Eli Lilly and Company received an additional approved <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/eli-lilly-drug-ixekizumab-receives-expanded-approval-for-non-radiographic-axial-spondyloarthritis/">indication for its drug Taltz® (ixekizumab)</a>, which is now approved to treat active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation. The approval is a milestone for Lilly, as ixekizumab is the first IL-17A antagonist to receive the FDA’s approval for nr-axSpA. Ixekizumab was first approved by the FDA in 2016 to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (this was expanded in March of this year to include pediatric patients). In 2017, the drug was also approved to treat adults with active psoriatic arthritis. Then, in 2019, it was approved to treat adults with active axSpA.Researchers recently compared the safety, efficacy, and pharmacodynamics of <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/eli-lilly-drug-ixekizumab-receives-expanded-approval-for-non-radiographic-axial-spondyloarthritis/">adalimumab manufactured by Hetero</a> and marketed as Mabura, versus reference adalimumab manufactured by Abbvie and marketed as Humira. “Results of this study demonstrated no clinically meaningful difference in efficacy, pharmacodynamics, and safety between test and reference treatment groups. Hence, the test adalimumab is being equally efficacious and safe biosimilar to the reference adalimumab for treatment of active [rheumatoid arthritis] RA in patients concomitantly on [methotrexate] therapy,” they concluded.Researchers recently assessed the <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/sarilumab-alone-or-in-combination-with-conventional-synthetic-dmards-safe-and-effective-for-most-ra-patients/">safety and efficacy of sarilumab</a> either as a monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with varying severities of RA. Overall, sarilumab was clinically superior as a monotherapy compared to adalimumab as well as in combination with csDMARDs compared to placebo plus csDMARDs across all patient demographic, disease characteristics, and prior treatments subgroups.<a href="https://www.docwirenews.com/condition-center/orthopedicscc/orthopedics-center-picks/how-has-the-covid-19-pandemic-impacted-spine-surgeons/">Orthopedic surgeons were significantly impacted by the COVID-19 pandemic</a>, and a recent analysis forecasted that surgery volume will not return to prepandemic levels for at least a year. An estimated 83.5% of all orthopaedic surgeries were delayed due to the <a href="https://www.docwirenews.com/home-page-editor-picks/the-covid-19-pandemic-latin-america-the-new-epicenter-company-starts-first-human-trial-of-coronavirus-antibody-therapy/">pandemic</a>. Of the estimated 16.5% that were permitted to go as scheduled, these were traumas, amputations, and oncological procedures; dislocations and fractures were performed if they were considered urgent cases. However, there are less data on how the pandemic has affected subspecialties.

Debra Patt, MD, PhD, MBA

ePROs and the Future of Cancer Care: Real-World Lessons From OncoPRO

Breast Cancer News

Izzah Nawaz

IBD on the Rise: Canterbury Study Warns of Growing Health Burden

Gastroenterology

Jordana Jampel

Paternal Distress Linked to Child Development Delays

Neurology

Latest News

Rheum Round-up: Ixekizumab’s Extended FDA Approval, RA Biosimilars Compared, and more

Rheumatology

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about the extended approval of ixekizumab, a comparison of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe